^
    Back
    Association details:
    Biomarker:KRAS amplification
    Cancer:Germ Cell Tumors
    Drug Class:MEK inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2018
    Title:

    Comprehensive genomic characterization of chemotherapy-resistant testicular germ cell tumors (TGCT).

    Published date:
    05/16/2018
    Excerpt:
    Clinical trials in molecularily-selected pts are warranted for refractory TGCT, particularly the high frequency of KRAS amplification may portend activity of MEK inhibitors.
    DOI:
    10.1200/JCO.2018.36.15_suppl.4555